FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for prediction of effectiveness of conservative treatment of oropharyngeal squamous cell carcinoma. Treatment is preceded by histological and immunohistochemical detection of tumour-infiltrating lymphocytes (TILs), markers p16, CD4 and CD8. If TILs are not less than 57.5%, CD4 is not less than 37.5%, CD8 is not less than 8.50% and p16 status is positive, regression of the primary tumour is predicted with conservative treatment.
EFFECT: method provides improved overall prognosis and quality of life of patients with oropharyngeal squamous cell carcinoma due to an individual approach to treatment, based on determination of molecular markers taking into account threshold values of their expression.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE OUTCOME OF SQUAMOUS CELL CARCINOMA OF THE TONGUE AND OROPHARYNX | 2019 |
|
RU2708786C1 |
| METHOD FOR PREDICTION OF DEVELOPMENT OF PROGRESSION IN A LONG PERIOD IN PATIENTS WITH SQUARE CELL CANCER OF THE HEAD AND NECK | 2021 |
|
RU2765013C1 |
| METHOD FOR PREDICTION OF DEVELOPING RECURRENCE AFTER COMBINED TREATMENT OF ORAL CANCER | 2023 |
|
RU2825290C1 |
| METHOD FOR PREDICTION OF PROGRESSION OF LOW-GRADE CERVICAL SQUAMOUS INTRAEPITHELIAL LESION WITH UNDERLYING HUMAN PAPILLOMAVIRUS INFECTION | 2021 |
|
RU2766719C1 |
| METHOD FOR PREDICTING TUMOUR RESISTANCE TO TETHEGETH THERAPY OF CETUXIMAB IN PATIENTS WITH PLANE-CELLULAR LANGUAGE OF LANGUAGE AND MULTIDISAL BOTTOM OF THE PTA | 2016 |
|
RU2626682C1 |
| METHOD FOR PREDICTING COURSE OF TUMOUR PROCESS IN PATIENTS WITH VULVAR CANCER | 2015 |
|
RU2613119C1 |
| METHOD OF TREATING LOCALLY ADVANCED OROPHARYNGEAL CANCER | 2020 |
|
RU2739294C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSTICS OF CERVICAL INTRAEPITHELIAL NEOPLASIAS ASSOCIATED WITH HUMAN PAPILLOMA VIRUS OF HIGH ONCOGENIC RISK | 2020 |
|
RU2754494C1 |
| METHOD OF PREDICTING RISK OF EARLY RECURRENCE OF ENDOMETRIAL SQUAMOUS CELL CARCINOMA IN PATIENTS WITH STAGE I OF DISEASE | 2023 |
|
RU2812609C1 |
| COMBINATION OF POXVIRUS ENCODING HUMAN PAPILLOMA VIRUS POLYPEPTIDES, AND IL-2 WITH ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824962C1 |
